![]() To date, there are no validated PRO tools in DT to capture the patient experience and efficacy of a drug. ![]() However, these endpoints do not capture improvements in clinical symptoms. Clinical trials in DT typically utilize response rates and progression free survival as primary endpoints. Background: Desmoid tumors (DT) are locally aggressive and cause significant morbidity.
0 Comments
Leave a Reply. |